Non Hodgkin Lymphoma Clinical Trial

Study Evaluating SC262 in Subjects With r/r B-cell Malignancies (VIVID)

Summary

SC262-101 is a Phase 1 study to evaluate SC262 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.

View Full Description

Full Description

This is an open-label, single arm, Phase 1, first-in-human (FIH) study to evaluate the safety and tolerability of SC262 administered intravenously (IV) following a standard lymphodepleting chemotherapy regimen of cyclophosphamide and fludarabine in subjects with Non Hodgkin's Lymphoma (NHL) who have received no more than 1 prior CD19-directed Chimeric Antigen Receptor T-Cells (CAR T) cell therapy. This study will be conducted in 2 parts. Dose finding using a 3+3 design in subjects with NHL. Dose expansion to further evaluate safety and efficacy at the recommended phase 2 dose (RP2D) in subjects with Large B-Cell Lymphoma (LBCL).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Male or Female Subject aged 18-80 years at the time of signing the informed consent

Histologic diagnosis of NHL (based on World Health Organization 2016 criteria) including:

LBCL, including Diffuse Large B Cell Lymphoma (DLBCL) not otherwise specified (NOS) (including DLBCL arising from indolent lymphoma), Primary Mediastinal Large B-Cell Lymphoma (PMBCL), High-Grade B-Cell Lymphoma (HGBCL), and Follicular Lymphoma (FL) Grade 3B
FL
Marginal Zone Lymphomas (MZL)
Mantle Cell Lymphoma (MCL)
Relapsed or refractory disease after no more than 1 prior CD19-directed CAR T cell therapy
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
At least 1 measurable (PET-positive) lesion per Lugano classification
Life expectancy ≥12 Weeks

Exclusion Criteria:

Prior CD22-directed therapy including CD22-directed CAR T cell therapy or other CD22 -directed antibody or cell therapy (e.g., Natural Killer (NK) cell)
History of central nervous system (CNS) involvement of lymphoma within 1 year prior to enrollment.
Autologous hematopoietic stem cell transplantation (HSCT) within 3 months before treatment with Lymphodepleting (LD) chemotherapy (or allogeneic HSCT at any time)
Active autoimmune disease or any other diseases requiring immunosuppressive therapy or corticosteroid therapy (defined as >10 mg/day prednisone or equivalent)
History or presence of CNS disorder, such as seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement, within 12 months of enrollment.

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 1

Estimated Enrollment:

35

Study ID:

NCT06285422

Recruitment Status:

Recruiting

Sponsor:

Sana Biotechnology

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Swedish Cancer Institute
Seattle Washington, 98104, United States More Info
Tori Braun
Contact
[email protected]
Emily Murakami
Contact
[email protected]
Krish Patel, MD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 1

Estimated Enrollment:

35

Study ID:

NCT06285422

Recruitment Status:

Recruiting

Sponsor:


Sana Biotechnology

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.